Cardiol Therapeutics (CRTPF) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the development of novel immuno-lipid therapies for treating heart failure and inflammation-related cardiovascular diseases. The company’s proprietary platform is built on synthetic formulations of cardiolipin, a naturally occurring mitochondrial lipid known to play a key role in cellular energy production and inflammatory regulation. By harnessing the anti-inflammatory properties of cardiolipin derivatives, Cardiol aims to address unmet needs in acute and chronic cardiovascular conditions.

Cardiol’s lead product candidate, CT-1 Microspheres, is designed for intravenous administration to hospitalized patients with acute decompensated heart failure. The formulation seeks to restore cardiac mitochondrial function while reducing inflammatory responses that exacerbate heart injury. In addition to CT-1 Microspheres, the company is advancing a pipeline of next-generation lipid therapeutics targeting chemotherapy-induced cardiomyopathy and other myocarditis indications.

Founded in 2014 and headquartered in Toronto, Ontario, Cardiol Therapeutics conducts its research and early-stage clinical trials in North America. The company leverages partnerships with academic institutions and contract research organizations across Canada and the United States to support its translational studies and upcoming Phase II programs. By focusing on diseases with significant morbidity and limited treatment options, Cardiol positions itself as an innovator in cardiovascular drug development.

Cardiol is led by President and Chief Executive Officer Jonathan K. Pak, MD, PhD, a cardiovascular researcher with more than 20 years of experience in drug discovery and development. The senior management team includes executives with backgrounds in biopharmaceutical development, regulatory affairs, and finance, reflecting the company’s commitment to advancing its lipid-based therapeutic platform through clinical proof-of-concept and eventual commercialization.

Key Stats

• Today's Range: $1.04 to $1.09
• 50-Day Range: $0.99 to $1.54
• 52-Week Range: $1.48 to $4.19
• Volume: 768,285 shs
• Average Volume: 67,097 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTPF Stock Analysis - Frequently Asked Questions

How have CRTPF shares performed this year?

Cardiol Therapeutics' stock was trading at $1.28 at the beginning of 2025. Since then, CRTPF stock has decreased by 16.4% and is now trading at $1.07.

How do I buy shares of Cardiol Therapeutics?

Shares of CRTPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CRTPF
• CIK: N/A
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A